Taste Of Capital
  • Politics
  • Investing
  • Business
  • Stock
Home Investing Eli Lilly stock sell-off ‘overdone’ as weight-loss pill remains ‘commercially viable’
Investing

Eli Lilly stock sell-off ‘overdone’ as weight-loss pill remains ‘commercially viable’

by admin August 8, 2025
August 8, 2025

Goldman Sachs analyst Asad Haider says investors are overreacting to the late-stage data Eli Lilly & Co (NYSE: LLY) reported for its experimental oral obesity pill, orforglipron, on Thursday.

Lilly reported blockbuster results for the second quarter and raised its full-year guidance on August 7th.

Still, the healthcare stock tumbled after management said the highest dose of “orforglipron” helped study participants lose 12.4% of their body weight on average, materially less than 15% expected.

However, long-term investors should consider buying Eli Lilly stock on the pullback because the sell-off was rather excessive and has created an opportunity to load up on a quality name at a deep discount, Haider told CNBC in an interview today.

Why orforglipron data still bodes well for Eli Lilly stock

According to Asad Haider, the market’s response to Lilly’s obesity pill trial data is disproportionate to the actual results.

While the drug missed the so-called “Street bar”, the analyst emphasized that orforglipron remains a commercially viable product.

On “Money Movers”, he dubbed the LLY pill scalable, especially in overseas markets, adding that the tolerability profile of the drug also held up well in the late-stage trial.

In Haider’s view, with 12.4% weight loss and minimal gastrointestinal side effects, orforglipron is bound to appeal to a broad segment of patients worldwide.

He’s convinced the sell-off in Eli Lilly shares reflects short-term sentiment rather than longer-term fundamentals – and that the pill will still play a meaningful role in the obesity treatment landscape.

Does the data alter orforglipron’s total addressable market?

While the trial results fell short of expectations, Haider doesn’t believe the total addressable market (TAM) for orforglipron has materially changed.

The obesity market remains vast and underpenetrated, with over 100 million obese individuals in the US and 900 million globally.

GLP-1 drugs currently reach only 3.0% of the US market, with projections for 15% penetration by the end of this decade.

Haider agreed that some of this opportunity may shift toward rival Novo Nordisk’s competing oral Semaglutide, but said orforglipron will still maintain relevance across diverse patient populations.

The drug’s convenience and scalability make it a viable option in a fragmented and growing market, which is why LLY stock is worth buying on the post-trial-data weakness.

Should you buy Eli Lilly stock on the pullback?

Goldman Sachs analyst Asad Haider maintained his “buy” rating on LLY shares today with a price target of $883, indicating potential upside of more than 35% from current levels.

Lilly’s strong Q2, driven mostly by its core franchises (Mounjaro and Zepbound) and raised outlook, warrants buying the dip this week.

Plus, a dividend yield of 0.94% makes up for another strong reason to have Eli Lilly stock in your long-term investment portfolio.

The post Eli Lilly stock sell-off ‘overdone’ as weight-loss pill remains ‘commercially viable’ appeared first on Invezz

previous post
Asian markets open: Nikkei gains 2.2%, gold hits record; Sensex to open down
next post
US eyes $50B monthly tariff boom, Commerce chief signals hard pivot

Related Posts

What made Terawulf stock soar 50% on Thursday and is...

August 15, 2025

Looking for the next Palantir? BofA says invest in this...

August 15, 2025

How India could turn into a global manufacturing powerhouse

August 15, 2025

Trump-Putin meeting stands to benefit these two European defense stocks

August 15, 2025

Dlocal shares jump 34% on strong quarterly results and upgraded...

August 15, 2025

Europe markets open: FTSE 100 hits new record, up 0.4%,...

August 15, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Stock News

    • Interview: Kairos Pharma CEO John Yu on ENV105’s potential & partnerships for growth

      August 15, 2025
    • Satoshi Nakamoto’s Bitcoin fortune climbs to $130.7 billion, surpassing Bill Gates

      August 15, 2025
    • Applied Materials falls 14% on weak forecast, China woes; long-term upside seen

      August 15, 2025
    • Wells Fargo sees buying opportunity in Tapestry shares after sell-off

      August 15, 2025
    • Nu Holdings stock price forecast after earnings: still a bargain?

      August 15, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TasteOfCapital.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
    Copyright © 2025 TasteOfCapital.com All Rights Reserved.

    Taste Of Capital
    • Politics
    • Investing
    • Business
    • Stock